RCD advises AlbaJuna Therapeutics, an IrsiCaixa spin-off, on the inflow of capital that will fund the development of antibodies against HIV

by RCD Rousaud Costas Duran

RCD – Rousaud Costas Duran has advised AlbaJuna Therapeutics, a spin-off from the IrsiCaixa AIDS Research Institute, on the investment of €3.75M by the pharmaceutical company Grifols, which will s...

Read more

Aelix Therapeutics completes Series A funding of € 11.5 M ($ 12.7 M)

by Caixa Capital Risc

The proceeds will support the development of the HTI immunogen as a therapeutic vaccine against HIV infection, up to the completion of a Phase 2 proof-of-concept efficacy trial in HIV-infected individ...

Read more
Subscribe to Directory
Write an Article

Highlight

3i closes second European CLO, Harvest V...

by 3i Group

3i Group plc (“3i” or “3i Group”), an international investor, ...

Clave Mayor y Fernando Fernández Garcé...

by Clave Mayor

La sociedad de capital riesgo Clave Mayor Corp. Industrial SCR Pyme SA...

Photos Stream